RapidAI Secures $75M for AI-Driven Stroke Care Solutions

What You Should Know: 

– RapidAI, a San Mateo, CA-based digital health company developing artificial intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases, today announced $75 million in Series C funding led by Vista Credit Partners, a subsidiary of Vista Equity Partners and strategic financing partner focused on the enterprise software, data and technology markets. 

– The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.

Clinical Decision Making & Workflow

RapidAI’s pioneering AI and workflow technology sets the standard for stroke care – the second leading cause of death globally. The company has built a comprehensive portfolio of stroke solutions, including Rapid NCCT Stroke – the first and only FDA-cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from non-contrast CT imaging. Rapid NCCT Stroke provides hospitals of all sizes and imaging capabilities greater access to imaging and decision support to address a wider population of patients. RapidAI has expanded into new disease states with FDA-cleared modules for cerebral aneurysm management and the identification and notification of suspected central pulmonary embolism. The company is also developing additional modules for other disease states.

imaging
health
medical
device
digital health
artificial intelligence
ai
software
fda
markets